Evidence map›Paper›PMID 41060476›Full record

ArticleJournal of molecular neuroscience : MN2025

The ADNP-Mediated Transcriptome Response to Ketamine Impairs the Cytoskeletal Protein Axis.

Claudio Peter D'Incal, Ligia Mateiu, Kevin De Man, Ellen Elinck, Illana Gozes, R Frank Kooy

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Claudio Peter D'IncalCognitive Genetics (COGNET), Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Ligia MateiuCognitive Genetics (COGNET), Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Kevin De ManCognitive Genetics (COGNET), Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Ellen ElinckCognitive Genetics (COGNET), Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
Illana GozesThe Elton Laboratory for Molecular Neuroendocrinology, Department of Human Molecular Genetics and Biochemistry, Gray Faculty of Medical and Health Sciences, Sagol School of Neuroscience and Adams Super Center for Brain Studies, Tel Aviv University, Tel Aviv, Israel.
R Frank KooyCognitive Genetics (COGNET), Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium. frank.kooy@uantwerpen.be.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

De novo variants in the Activity-Dependent Neuroprotective Protein (ADNP) gene cause the autistic Helsmoortel-Van der Aa syndrome with patients showing mild to disastrous phenotypes impacting brain functioning, behavior, and organ functions. In this respect, two treatment strategies have been proposed to alleviate symptoms in patients with this syndrome: (1) the ADNP-derived octapeptide investigational drug NAP (davunetide), which enhances ADNP's ability to target cytoskeletal deficits, and (2) subnarcotic levels of ketamine, which are suggested to increase endogenous ADNP mRNA levels. Here, we focus on the perspective of ketamine and investigated the transcriptomic response of low-dose and high-dose ketamine applications at different time points, experimentally controlled by the non-toxic drug NAP, in lymphoblastoid cell lines obtained from individuals with Helsmoortel-Van der Aa syndrome. Transcriptome profiling was performed at baseline conditions, followed by dose (low or high) and time (40 min or 4 h)-dependent ketamine application in patient and control lymphoblastoid cell lines. We showed that ketamine affected ADNP expression levels in a dose- and time-dependent manner with only toxic ketamine concentrations increasing ADNP protein levels. Ketamine application also triggered a transcriptomic response with profound gene expression alterations centered around processes such as immune response-regulating signaling pathways and cell fate commitment at low-dose ketamine, together with organelle assembly and cytoskeletal dysregulation at high doses. A parallel control experiment with NAP under the same experimental conditions did not induce detectable gene expression differences in patient-derived cell lines. The ketamine-induced cytoskeletal alterations were functionally studied using immunoblotting, showing a disturbed expression of α-tubulin, β-actin, and to a minor extent microtubule-associated protein EB3 in patient-derived lymphoblastoid cells. Ketamine upregulates wild-type ADNP transcript and protein levels in a dose- and time-dependent manner in patient-derived lymphoblastoid cell lines from individuals with Helsmoortel-Van der Aa syndrome, while inducing a transcriptomic response that affects key processes including immune system signaling and cytoskeletal organization.

Indexed as

KetamineNerve Tissue ProteinsTranscriptomeCell LineHomeodomain ProteinsHumansLymphocytesADNP protein, humanHomeodomain ProteinsKetamineNerve Tissue ProteinsActivity-Dependent Neuroprotective Protein (ADNP)Helsmoortel-Van der Aa syndrome (HVDAS)KetamineMicrotubule-End Binding ProteinsNAP (davunetide)

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.